The lancet oncology

• Latest
• Best
• Search…

• The lancet oncology · May 2018

  Comment

  Nilotinib in locally advanced pigmented villonodular synovitis: challenges of a new targeted therapy.

  no abstract available

  expand abstract… or not…

• The lancet oncology · May 2018

  Comment

  Modified XELIRI (capecitabine plus irinotecan) for metastatic colorectal cancer.

  no abstract available

  keep going… or not…

• The lancet oncology · May 2018

  Comment Letter

  Body-mass index and metastatic melanoma outcomes - Authors' reply.

  no abstract available

  explore further… mark as read…

• The lancet oncology · May 2018

  Comment

  Patient-reported outcomes: an essential component of oncology drug development and regulatory review.

  no abstract available

  keep going… mark as read…

• The lancet oncology · May 2018

  Randomized Controlled Trial Multicenter Study Comparative Study

  Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.

  Combined BRAF-MEK inhibitor therapy is the standard of care for BRAFV600-mutant advanced melanoma. We investigated encorafenib, a BRAF inhibitor with unique target-binding properties, alone or in combination with the MEK inhibitor binimetinib, versus vemurafenib in patients with advanced BRAFV600-mutant melanoma. ⋯ Array BioPharma, Novartis.

  keep going… or not…